Ambrx Biopharma Inc (DELISTED) (AMAM:DL)
27.99
+0.01
(+0.04%)
USD |
NASDAQ |
Mar 06, 16:00
28.00
+0.01
(+0.04%)
After-Hours: 20:00
Ambrx Biopharma Cash from Operations (Quarterly): -18.88M for Sept. 30, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | -18.88M |
| June 30, 2023 | -13.15M |
| March 31, 2023 | -12.97M |
| December 31, 2022 | -12.70M |
| Date | Value |
|---|---|
| September 30, 2022 | -15.78M |
| June 30, 2022 | -14.53M |
| March 31, 2022 | -25.66M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-25.66M
Minimum
Mar 2022
-12.70M
Maximum
Dec 2022
-16.24M
Average
-14.53M
Median
Jun 2022
Cash from Operations (Quarterly) Benchmarks
| Johnson & Johnson | 3.657B |
| Axonics Inc | -9.236M |
| Harpoon Therapeutics Inc (DELISTED) | -16.53M |
| Merck & Co Inc | 3.09B |
| RayzeBio inc (DELISTED) | -45.26M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 6.164M |
| Cash from Financing (Quarterly) | 9.71M |
| Free Cash Flow | -58.82M |
| Free Cash Flow Per Share (Quarterly) | -0.308 |
| Free Cash Flow to Equity (Quarterly) | -19.18M |
| Free Cash Flow to Firm (Quarterly) | -19.18M |
| Free Cash Flow Yield | -0.81% |